AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Krystal Biotech Analyst Ratings: Bullish Sentiment with 6 Buy Ratings
ByAinvest
Wednesday, Aug 6, 2025 3:10 am ET1min read
Krystal Biotech analyst ratings reveal a mix of sentiments with 8 analysts having made evaluations in the last 3 months. The average 12-month price target is $203.88, with a high estimate of $240.00 and a low estimate of $155.00. This current average has decreased by 3.63% from the previous average price target of $211.57. Analysts have issued a range of ratings from "Buy" to "Neutral", with some adjusting their ratings and price targets in response to the company's performance.
Krystal Biotech Inc. (KRYS) has seen a mixed bag of analyst sentiments in the past three months, with eight analysts providing evaluations. The average 12-month price target for the company has decreased by 3.63% from $211.57 to $203.88, with a high estimate of $240.00 and a low estimate of $155.00 [3].The ratings range from "Buy" to "Neutral," with analysts adjusting their positions based on the company's performance. Alec Stranahan of BofA Securities lowered the price target to $182 from $192 while maintaining a "Buy" rating, citing concerns about the near-term growth trajectory due to patient pausing trends and decreased Vyjuvek revenues [1, 2].
Geulah Livshits of Chardan Capital and Joseph Pantginis of HC Wainwright & Co. maintained their "Buy" ratings and price targets at $219.00 and $240.00, respectively, indicating continued bullish sentiment [3]. Carly Kenselaar of Citigroup raised the rating to "Neutral" with a price target of $176.00, reflecting cautious optimism [3].
Key financial indicators highlight Krystal Biotech's strong market position. The company achieved a remarkable revenue growth rate of 94.88% in the past three months, with an impressive net margin of 40.52% and a debt-to-equity ratio of 0.01, indicating robust financial health [3].
Analysts' ratings are crucial for investors, providing insights into the company's performance and future prospects. However, it is essential to consider these evaluations alongside other financial indicators and market trends to make informed investment decisions.
References:
[1] https://finance.yahoo.com/news/krystal-biotech-price-target-lowered-160028850.html
[2] https://www.investing.com/news/analyst-ratings/krystal-biotech-stock-price-target-lowered-to-182-at-bofa-on-growth-concerns-93CH-4168444
[3] https://www.benzinga.com/insights/analyst-ratings/25/08/46858403/what-8-analyst-ratings-have-to-say-about-krystal-biotech
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet